Skip to content
Precision for Medicine
Contact

Essais et imagerie cellulaires

Essais cellulaires en formats 2D et 3D sur un large éventail de types de cellules primaires humaines
Nos tests ont fourni des données à l'appui d'une série d'indications thérapeutiques différentes allant du diabète à la fibrose et à l'oncologie, mais notre objectif principal reste la recherche sur les maladies anti-inflammatoires et auto-immunes. Notre approche personnalisée permet de développer des tests adaptés aux besoins spécifiques de votre programme. Outre le développement d'essais, l'étendue de nos plateformes analytiques nous permet d'offrir une gamme complète de critères d'évaluation, y compris la libération de médiateurs/cytokines, les changements dans l'expression génétique, l'ICC et l'imagerie cellulaire à haut contenu.

Essais cellulaires adaptés à votre programme

Exemples de types de cellules utilisées pour le développement de l'essai


  • Cellules sanguines : PBMC, monocytes, lymphocytes, neutrophiles, macrophages dérivés de monocytes
  • Cellules de la peau : kératinocytes, fibroblastes
  • Cellules pulmonaires : cellules épithéliales bronchiques, macrophages alvéolaires, cellules alvéolaires de type II, cellules musculaires lisses, cellules épithéliales tumorales, fibroblastes associés au cancer
  • Cellules hépatiques : hépatocytes, cellules de Kupffer, cellules stellaires
  • Autres types de cellules : îlots pancréatiques, fibroblastes synoviaux

Formats de la culture


  • 2D
    • plaques multipuits
    • transpuits
  • 3D
    • interface air-liquide
    • avec ou sans matrice
    • simple ou co-culture

Essais cellulaires et types d'effets


  • Libération de cytokines
  • Viabilité/prolifération cellulaire
  • Apoptose
  • Changements dans l'expression des gènes
  • Activité/libération enzymatique
  • Perméabilité de la barrière
  • Migration cellulaire
  • ICC
  • Immunofluorescence multiplex/imagerie cellulaire à haut contenu
  • Western blotting automatisé (Jess™)

TYPE(S) DE CELLULEEXEMPLES D'ASSAISONNEMENT

Sang total

Inhibition de la libération de TNFα et d'IL-6 stimulée par le LPS

Stimulation (PHA) et inhibition (CsA) de la prolifération cellulaire

PBMCs

Inhibition de la libération d'IL-2 et d'IFNγ stimulée par OKT3 (CD3)

Inhibition de la libération de TNFα stimulée par CD3:CD28

Monocytes et macrophages dérivés des monocytes

Inhibition de la libération de TNFα stimulée par le LPS

Lymphocytes

Inhibition de la libération d'IL-2 stimulée par OKT3 (CD3)

Neutrophiles

Transmigration (+HUVEC)

Libération de superoxyde

HUVECs

Inhibition de la libération d'IL-8 et de MCP-1 stimulée par la thrombine

Hépatocytes

Inhibition de la libération d'IL-6 et d'IL-8 stimulée par le TNFα Induction de CYP (ARNm)

Stellates

Changements induits par le TGF-β1 dans l'expression des gènes fibrogènes et le dépôt de collagène

Macrophages alvéolaires

Inhibition de la libération de TNFα stimulée par le LPS

Kératinocytes

Stimulation (IL-4) et inhibition (CsA) de la prolifération cellulaire

Fibroblastes synoviaux (RA)

Essai validé pour le criblage de nouveaux anticorps thérapeutiques anti-TNFα (biosimilaires)

Whole blood

Inhibition of LPS stimulated TNFα and IL-6 release

Stimulation (PHA) and inhibition (CsA) of cell proliferation

PBMCs

Inhibition of OKT3 (CD3) stimulated IL-2 and IFNγ release

Inhibition of CD3:CD28 stimulated TNFα release

Monocytes & Monocyte-derived Macrophages

Inhibition of LPS stimulated TNFα release

Lymphocytes

Inhibition of OKT3 (CD3) stimulated IL-2 release

Neutrophils

Transmigration (+HUVEC)

Superoxide release

HUVECs

Inhibition of thrombin stimulated IL-8 and MCP-1 release

Hepatocytes

Inhibition of TNFα stimulated IL-6 and IL-8 release CYP induction (mRNA)

Stellates

TGF-β1-induced changes in fibrogenic gene expression and collagen deposition

Alveolar macrophages

Inhibition of LPS stimulated TNFα release

Keratinocytes

Stimulation (IL-4) and inhibition (CsA) of cell proliferation

Synovial fibroblasts (RA)

Validated assay for screening novel anti-TNFα therapeutic antibodies (biosimilars)

Étude de cas : validation d'un essai biologique à l'appui d'une demande d'autorisation de mise sur le marché auprès de l'EMA

Détails :

  • Essai 2D
  • Fibroblastes synoviaux provenant de donneurs atteints de polyarthrite rhumatoïde

Développement de l'essai inclus :

  • Inhibiteur standard de référence
  • Titrage du stimulus
  • Sélection du marqueur sentinelle
  • Effet de la formulation

La validation de l'essai comprend

  • Linéarité et gamme
  • Puissance relative
  • Parallélisme
  • la spécificité
  • Précision intra/inter-essai
  • Dépistage des biosimilaires

Precision a également réalisé un screening biosimilaire comparant la puissance relative à Humira.


Résultats

1268-IL-6-RA-syn-fibs-2

Services connexes

  • Explorer
    lmmunohistochimie (IHC)
    diapositive de tissu

    lmmunohistochimie (IHC)

    Solutions d'IHC de bout en bout, comprenant la mise en kit, la logistique des échantillons, la coloration via toutes les principales plates-formes et les services de pathologie internes.
    Explorer
    diapositive de tissu

    lmmunohistochimie (IHC)

    Solutions d'IHC de bout en bout, comprenant la mise en kit, la logistique des échantillons, la coloration via toutes les principales plates-formes et les services de pathologie internes.
    Explorer
  • Explorer
    cytométrie

    Cytométrie en flux

    Cytométrie en flux standard et spectrale, sur des instruments de qualité recherche et validés CLIA.
    Explorer

    Cytométrie en flux

    Cytométrie en flux standard et spectrale, sur des instruments de qualité recherche et validés CLIA.
    Explorer
  • Explorer
    Multiplex

    Immunofluorescence multiplex (mIF)

    Services automatisés d'immunofluorescence multiplex permettant la visualisation quantitative de jusqu'à 9 marqueurs dans les biopsies tissulaires et liquides.
    Explorer

    Immunofluorescence multiplex (mIF)

    Services automatisés d'immunofluorescence multiplex permettant la visualisation quantitative de jusqu'à 9 marqueurs dans les biopsies tissulaires et liquides.
    Explorer

Explorer le blog de Precision

Lisez notre blog pour en savoir plus et découvrir les travaux soutenus par Precision.

Découvrez notre blog
Read: Reflect on 20 Years of Cancer Research with MIRROR Biospecimens Reflect on 20 Years of Cancer Research with MIRROR Biospecimens

Translational Research - Biospecimens

Reflect on 20 Years of Cancer Research with MIRROR Biospecimens

|
    has not third author: true, (SizeLimitingPyMap: {main={hs_id=199448088864, hs_child_table_id=0, hs_updated_at=1762810484868, hs_published_at=1763063316762, avatar=Image{width=1200,height=1200,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/Kaylee%20Mueller.png',altText='Kaylee Mueller',fileId=199456336149}, lastname=Mueller, hs_initial_published_at=1762810487482, hs_created_by_user_id=26433386, hs_created_at=1762810467146, hs_is_edited=false, hs_deleted_at=0, name=Kaylee, slug=kaylee-mueller, hs_updated_by_user_id=26433386}, second={}, third={}})
  • Kaylee Mueller avatar

    Kaylee Mueller
Découvrir
Read: Lost in Translation: Turning Multi-omic Chaos into Clinical Clarity Lost in Translation: Turning Multi-omic Chaos into Clinical Clarity

Translational Research - Lab Services

Lost in Translation: Turning Multi-omic Chaos into Clinical Clarity

|
    has third author: false, (SizeLimitingPyMap: {main={hs_id=159488778872, hs_child_table_id=0, hs_updated_at=1744653337128, hs_published_at=1763063316762, description=Visionary leader with decades of distinguished biotechnology and clinical translational research experience. Founded ApoCell in 2004 and later was instrumental in developing and commercializing the ApoStream® rare-cell liquid biopsy technology. Globally recognized cancer researcher and the author of more than 100 peer-reviewed publications. Dedicated and committed to improving the lives of patients with debilitating diseases., avatar=Image{width=576,height=576,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/Headshots/Headshots%20no%20background/Darren%20Davis.webp',altText='Darren Davis',fileId=165891429693}, linkedin=https://www.linkedin.com/in/drdarrendavis, team=[{id=163072475009, name='Translational Sciences Leadership'}], hs_name=, hs_path=, lastname=Davis, PhD, hs_initial_published_at=1763062961222, hs_created_at=1709645745103, hs_is_edited=false, hs_deleted_at=0, name=Darren, job=Senior Vice President, Translational Sciences, slug=darren-davis, email=, hs_updated_by_user_id=26433386}, second={hs_id=167888548278, hs_child_table_id=0, hs_updated_at=1722451546286, hs_published_at=1763063316762, description=Pharma industry veteran and expert at biomarker-driven clinical trial design and execution. Leader of biomarker and drug development programs for pharmaceutical and diagnostics companies, as well as the National Institutes of Health. Spearheaded the discovery of pharmacodynamic biomarkers and novel targets for inflammatory disease therapy., avatar=Image{width=576,height=576,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/Headshots/Headshots%20no%20background/Deb%20Phippard.webp',altText='Deb Phippard',fileId=165892372605}, linkedin=https://www.linkedin.com/in/deb-phippard-103b54, team=[{id=163072475009, name='Translational Sciences Leadership'}], hs_name=, hs_path=, lastname=Phippard, PhD, hs_initial_published_at=1716194887110, hs_created_by_user_id=2737751, hs_created_at=1716194842710, hs_is_edited=false, hs_deleted_at=0, name=Deborah, job=Chief Scientific Officer, slug=deborah-phippard-translational-sciences, email=, hs_updated_by_user_id=26433386}, third={hs_id=159488778883, hs_child_table_id=0, hs_updated_at=1762803857448, hs_published_at=1763063316762, description=Jie Yang, PhD is a Scientific Liaison for Precision for Medicine. An Immunologist by training with extensive industry expertise in designing translational assays for biomarker-guided clinical trials. Conducted postdoctoral research on immuno-oncology at MD Anderson Cancer Center. Led biomarker assay development and collaborated on the implementation of new technologies for pre-clinical and clinical studies conducted by pharmaceutical and biotech companies for drug development., avatar=Image{width=885,height=886,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/Headshots/Headshots%20no%20background/Jie-Yang.png',altText='Jie-Yang',fileId=167372215352}, linkedin=https://www.linkedin.com/in/jie-yang-0528221b, hs_name=, hs_path=, lastname=Yang, PhD, hs_initial_published_at=1763062961222, hs_created_at=1709645745114, hs_is_edited=false, hs_deleted_at=0, name=Jie, job=, slug=jie-yang, email=, hs_updated_by_user_id=26433386}})
  • Darren D. avatar Deborah P. avatar Jie Y. avatar

  • Darren D.

    Deborah P.

    Jie Y.
Découvrir
Read: Investor Relations, Clinical Operations, and the Future of Biotech Financing Investor Relations, Clinical Operations, and the Future of Biotech Financing

Clinical Trials - Translational Research - Early Phase Research

Investor Relations, Clinical Operations, and the Future of Biotech Financing

|
    has not third author: true, (SizeLimitingPyMap: {main={hs_id=164725548862, hs_child_table_id=0, hs_updated_at=1716454315513, hs_published_at=1763063316762, description=Teresa is a respected business development strategist, building successful clinical programs for clients in Massachusetts. She is an innovator of fresh approaches to biomarker planning, translational solutions, and clinical study design. Her experience spans the execution of Phase 1-4 clinical trials, specialty lab services, companion and in vitro diagnostic strategies, and biomarker data management., avatar=Image{width=700,height=700,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/Headshots/Headshots%20no%20background/Teresa-Pokladowski-300x300.png',altText='Teresa-Pokladowski-300x300',fileId=168135942975}, linkedin=https://www.linkedin.com/in/teresapokladowski/, lastname=Pokladowski, hs_initial_published_at=1713363230550, hs_created_by_user_id=5166971, hs_created_at=1713362443509, hs_is_edited=false, hs_deleted_at=0, name=Teresa, job=Regional Vice President, Clinical Business Solutions, North America, slug=teresa-pokladowski, hs_updated_by_user_id=26433386}, second={hs_id=197608580658, hs_child_table_id=0, hs_updated_at=1760465121471, hs_published_at=1763063316762, description=Hannah Dereseiwicz is a strategic force in investor relations, helping biotech innovators translate complex science into compelling narratives that drive engagement and growth. With a track record spanning commercial launches, M&A activity, and high-stakes communications, she brings clarity, confidence, and momentum to every stage of a company’s journey. Hannah’s approach is defined by the three A’s—ambitious, approachable, and authentic—making her a trusted partner for teams looking to elevate their story and connect with the audiences that matter most., avatar=Image{width=636,height=476,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/Hannah%20Deresiewicz.webp',altText='Hannah Deresiewicz',fileId=197608718507}, lastname=Deresiewicz, hs_initial_published_at=1760465283803, hs_created_by_user_id=26433386, hs_created_at=1760464991513, hs_is_edited=false, hs_deleted_at=0, name=Hannah, job=Executive Vice President, Managing Director Precision AQ – Investor Relations & External Communications, slug=hannah-deresiewicz, hs_updated_by_user_id=26433386}, third={}})
  • Teresa P. avatar

    Teresa P.
  • Hannah D. avatar

    Hannah D.
Découvrir
Loading...